TY - JOUR
T1 - Selection of medications to prevent stroke among individuals with atrial fibrillation
T2 - Update on prevention of stroke in patients with AF
AU - Testa, Luca
AU - Fasano, Alfonso
AU - De Sanctis, Valerio
AU - Latini, Roberto Adriano
AU - Latib, Azeem
AU - Oreglia, Jacopo
AU - De Marco, Federico
AU - Agnifili, Mauro
AU - Casavecchia, Matteo
AU - Talarico, Giovanni Paolo
AU - Lanotte, Stefania
AU - Pizzocri, Samuele
AU - Mattioli, Roberto
AU - Mantica, Massimo
AU - Bedogni, Francesco
PY - 2013/10
Y1 - 2013/10
N2 - Opinion statement: Vitamin K antagonists have been the only available orally active anticoagulants for decades. Although effective, their numerous limitations have driven the introduction of new oral anticoagulants (NOAs) that showed effectiveness at fixed doses without the need for routine coagulation monitoring. However, the safety and efficacy observed in controlled clinical trials may be hard to translate in clinical practice. Clinical conditions as well as drug interactions may considerably impact on patient outcomes. Moreover, the inability to monitor the pharmacological activity of NOAs and the absence of any antidote in the setting of bleeding or emergent invasive procedures may limit their use. Vitamin K antagonists will be still used in many circumstances, including patients with an optimal control of the INR, with mechanical heart valves, and other indications for which these new agents have not been investigated. Nevertheless, these new agents will reduce the burden of anticoagulation management at the patient as well as Health Care level.
AB - Opinion statement: Vitamin K antagonists have been the only available orally active anticoagulants for decades. Although effective, their numerous limitations have driven the introduction of new oral anticoagulants (NOAs) that showed effectiveness at fixed doses without the need for routine coagulation monitoring. However, the safety and efficacy observed in controlled clinical trials may be hard to translate in clinical practice. Clinical conditions as well as drug interactions may considerably impact on patient outcomes. Moreover, the inability to monitor the pharmacological activity of NOAs and the absence of any antidote in the setting of bleeding or emergent invasive procedures may limit their use. Vitamin K antagonists will be still used in many circumstances, including patients with an optimal control of the INR, with mechanical heart valves, and other indications for which these new agents have not been investigated. Nevertheless, these new agents will reduce the burden of anticoagulation management at the patient as well as Health Care level.
KW - Atrial fibrillation
KW - Hemorrhagic complications
KW - New oral anticoagulants
KW - Prevention
KW - Stroke
KW - Vitamin K antagonists
UR - http://www.scopus.com/inward/record.url?scp=84885176595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885176595&partnerID=8YFLogxK
U2 - 10.1007/s11940-013-0248-3
DO - 10.1007/s11940-013-0248-3
M3 - Article
C2 - 23794179
AN - SCOPUS:84885176595
SN - 1092-8480
VL - 15
SP - 583
EP - 592
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 5
ER -